aop2014
Recombinant proteinexperimental
Clinical trial activity
1 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Feb 2, 2017 (NCT03003325)
Timeline
2010s
- Jan 1, 2017
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Interferon alphaSupplementation
Interferon alpha supplementation
- Interferon alpha-17 (IFNA17) ↗
- Interferon alpha-4 (IFNA4) ↗
- Interferon alpha-14 (IFNA14) ↗
- Interferon alpha-6 (IFNA6) ↗
- Interferon alpha-8 (IFNA8) ↗
- Interferon alpha-5 (IFNA5) ↗
- Interferon alpha-10 (IFNA10) ↗
- Interferon alpha-2 (IFNA2) ↗
- Interferon alpha-1/13 (IFNA1; IFNA13) ↗
- Interferon alpha-7 (IFNA7) ↗
- Interferon alpha-21 (IFNA21) ↗
- Interferon alpha-16 (IFNA16) ↗
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- aop2014
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03003325 | Phase 2 | Feb 2, 2017 | AOP Orphan Pharmaceuticals AG, Bankura Sammilani Medical College, University of Milan |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AOP Orphan Pharmaceuticals AG | For profit | 1 | 0 | 1 | 2017 |
| Bankura Sammilani Medical College | Academic/Hospital | 1 | 0 | 1 | 2017 |
| University of Milan | Academic/Hospital | 1 | 1 | 1 | 2017 |
3 organizations
Page 1 / 1